Natera’s Post

🎙️ If you missed any part of the interview with Prof. Vogl, don't worry! The full interview is available now on our website. Vogl, Thomas Prof. emphasizes the importance of safety and effectiveness in treating liver cancer patients with DSM-TACE and chemoembolization. Click below and enjoy reading the full version. #MagleGroup #MaglePharmaCept #DSM #Embolization #EmboCept® S DSM 50 µm #chemoembolization

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Samuel Yamshon, MD, Weill Cornell Medicine, examines the efficacy of using CAR T-cell therapy to treat elderly patients with R/R #DLBCL. Learn more: https://lnkd.in/ehy_2QyT #Oncology #Oncologist #GDUHem #GDUHem2024 #OncologyNews #Hematology

Continuing with our look at a recent article in press (Guerrero-Ramos et al, European Urology Oncology, May 2024) on delivery systems and pharmacotherapeutic approaches for the treatment of non-muscle-invasive bladder cancer (NMIBC), including HIVEC® with the Combat BRS (Bladder Recirculation System)…   Considering BCG-unresponsive high-risk (HR) NMIBC, the authors note:     “At present, and according to the EAU guidelines, RC [radical cystectomy] is the preferred treatment for these patients, supported by level 3 evidence. The guidelines recommend that patients unfit for or unwilling to undergo RC should be included in clinical trials exploring novel therapies. When trials are unavailable or patients are deemed unfit, device-assisted chemotherapy represents an option.   “In this context, only the radiofrequency-induced thermochemotherapy effect (RITE) has been specifically investigated in a randomised clinical trial. The HYMN study randomised 104 patients with high-grade NMIBC… to receive either RITE or the institute’s standard treatment, which encompassed BCG, MMC, or electromotive drug administration (EMDA). "The trial was prematurely closed because the CIS recurrence rate in the group treated with RITE was higher than expected. The study found no benefit with RITE over the control treatment in terms of the 24-mo DFS rate or the 3-mo CIS CR rate.”   More tomorrow!   *Guerrero-Ramos et al, World Journal of Urology 2022   #medicalinnovation #bladdercancer #HIVEC #CombatMedical

Subcutaneous daratumumab with VRd improves progression-free survival in multiple myeloma #ChronicDisease #Oncology

REGISTER NOW for our upcoming Oncology Live CME Series virtual course on Treatment of Hepatocellular Carcinoma: A Multi-Disciplinary Approach. June 12, 2024 5:30-6:30PM PT Recent advances in therapeutic options for hepatocellular carcinoma have challenged prior paradigms for treatment. We will discuss how surgical resection and liver transplant, locoregional therapies, and systemic therapies are used in current clinical practice and how they are interfacing in the future with a multimodal approach. Topics discussed will include: * Systemic therapy options * Emerging clinical trials for advanced stage HCC * Treatment options for early-stage HCC, including surgical resection and liver transplantation * Locoregional treatment options for early and intermediate stage HCC, for patients who are not candidates for surgical resection and liver transplantation The target audience for this course includes medical oncologists, surgical oncologists, hepatologists, interventional radiology, advanced practice providers, nurses, students, residents and fellows. REGISTRATION IS FREE! To register, go to: https://lnkd.in/gGRWTGY5 #OncologyLiveCME #hepatocellularcarcinoma #HCC #livertransplant #medicaloncology #oncology #hepatology #interventionalradiology #medicaloncologist #surgicaloncologist #hepatologists #meded #cme #cpdoffice

Perioperative pembrolizumab with chemotherapy for gastric and gastroesophageal junction adenocarcinoma improves pathological complete response rate compared with placebo #ChronicDisease #Oncology

Continuing with our look at a recent article in press (Guerrero-Ramos et al, European Urology Oncology, May 2024) on delivery systems and pharmacotherapeutic approaches for the treatment of non-muscle-invasive bladder cancer (NMIBC), including HIVEC® with the Combat BRS (Bladder Recirculation System)…   Considering BCG-unresponsive high-risk (HR) NMIBC, the authors note:     “At present, and according to the EAU guidelines, RC [radical cystectomy] is the preferred treatment for these patients, supported by level 3 evidence. The guidelines recommend that patients unfit for or unwilling to undergo RC should be included in clinical trials exploring novel therapies. When trials are unavailable or patients are deemed unfit, device-assisted chemotherapy represents an option.   “In this context, only the radiofrequency-induced thermochemotherapy effect (RITE) has been specifically investigated in a randomised clinical trial. The HYMN study randomised 104 patients with high-grade NMIBC… to receive either RITE or the institute’s standard treatment, which encompassed BCG, MMC, or electromotive drug administration (EMDA). The trial was prematurely closed because the CIS recurrence rate in the group treated with RITE was higher than expected. The study found no benefit with RITE over the control treatment in terms of the 24-mo DFS rate or the 3-mo CIS CR rate.”   More tomorrow!   *Guerrero-Ramos et al, World Journal of Urology 2022   #medicalinnovation #bladdercancer #HIVEC #CombatMedical

Continuing with our look at a recent article in press (Guerrero-Ramos et al, European Urology Oncology, May 2024) on delivery systems and pharmacotherapeutic approaches for the treatment of non-muscle-invasive bladder cancer (NMIBC), including HIVEC® with the Combat BRS (Bladder Recirculation System)…   Considering BCG-unresponsive high-risk (HR) NMIBC, the authors note:     “At present, and according to the EAU guidelines, RC [radical cystectomy] is the preferred treatment for these patients, supported by level 3 evidence. The guidelines recommend that patients unfit for or unwilling to undergo RC should be included in clinical trials exploring novel therapies. When trials are unavailable or patients are deemed unfit, device-assisted chemotherapy represents an option.   “In this context, only the radiofrequency-induced thermochemotherapy effect (RITE) has been specifically investigated in a randomised clinical trial. The HYMN study randomised 104 patients with high-grade NMIBC… to receive either RITE or the institute’s standard treatment, which encompassed BCG, MMC, or electromotive drug administration (EMDA). "The trial was prematurely closed because the CIS recurrence rate in the group treated with RITE was higher than expected. The study found no benefit with RITE over the control treatment in terms of the 24-mo DFS rate or the 3-mo CIS CR rate.”   More tomorrow!   *Guerrero-Ramos et al, World Journal of Urology 2022   #medicalinnovation #bladdercancer #HIVEC #CombatMedical

𝐕𝐨𝐫𝐚𝐬𝐢𝐝𝐞𝐧𝐢𝐛 𝐢𝐦𝐩𝐫𝐨𝐯𝐞𝐬 𝐩𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧-𝐟𝐫𝐞𝐞 𝐬𝐮𝐫𝐯𝐢𝐯𝐚𝐥 𝐢𝐧 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐠𝐫𝐚𝐝𝐞 𝟐 𝑰𝑫𝑯-𝐦𝐮𝐭𝐚𝐧𝐭 𝐠𝐥𝐢𝐨𝐦𝐚 Isocitrate dehydrogenase (𝐼𝐷𝐻)-mutant grade 2 gliomas are malignant brain tumours that cause considerable disability and premature death. Vorasidenib is an investigational drug that crosses the blood-brain barrier and inhibits mutated IDH1 and IDH2. Recently published in 𝑇ℎ𝑒 𝑁𝑒𝑤 𝐸𝑛𝑔𝑙𝑎𝑛𝑑 𝐽𝑜𝑢𝑟𝑛𝑎𝑙 𝑜𝑓 𝑀𝑒𝑑𝑖𝑐𝑖𝑛𝑒, the results of the INDIGO trial showed that vorasidenib significantly improves progression-free survival and delayed the time to the next intervention in patients with residual or recurrent grade 2 𝐼𝐷𝐻-mutant glioma. #cancer #glioma #oncology #vorasidenib   https://lnkd.in/e-keBHHE